Mann Eye Institute and Laser Center Acquires Its Third ALLEGRETTO WAVE System From WaveLight.

New EYE-Q Platform Provides Fastest LASIK Treatments in US

HOUSTON -- Mann Eye Institute and Laser Center announced today that it has installed a new LASIK system that delivers the fastest laser vision correction treatments available in the country. The ALLEGRETTO WAVE([R]) Eye-Q is the third LASIK system that Mann Eye Institute has purchased from WaveLight, Inc., during the past three years.

"We have found that ALLEGRETTO WAVE systems deliver the most predictable and reliable outcomes, as evidenced by the majority of our patients achieving better than 20/20 vision after LASIK," said Michael Mann, M.D., FACS of the Mann Eye Institute and Laser Center. "Due to the Eye-Q's amazing speed, we now have the opportunity to provide these same great results to our patients in less time than ever before."

The Eye-Q system, manufactured by WaveLight AG, corrects one diopter of nearsightedness or farsightedness in just two seconds. Therefore, the average treatment time to complete the LASIK procedure is typically between just eight and ten seconds. Shorter treatments could potentially improve the accuracy of corrections after LASIK. In addition, patient comfort is enhanced as the amount of time required to focus during the procedure is significantly reduced.

The Eye-Q is a next generation system featuring WaveLight's proprietary PerfectPulse Technology(TM) to ensure maximum safety at high speed. PerfectPulse Technology was specifically developed to monitor and control each laser pulse that is delivered to the cornea during the LASIK procedure. Another component of this technology is a high speed, active eye-tracking device which monitors eye movement 400 times per second and adjusts the laser beam accordingly in less than six milliseconds.

This new LASIK platform also features WaveLight's proprietary Wavefront Optimized[TM] technology, which has been shown to preserve the natural shape of the cornea and prevent the induction of optical errors that could lead to night vision problems or loss of contrast sensitivity (the ability to see the images crisply).

"We believe Mann Eye Institute's twenty-year commitment to personalized patient care is reflected in the state-of-the-art technologies they provide as well as the competence and expertise of their staff," said Wolfgang Tolle, CEO of WaveLight, Inc. "As valued customers to WaveLight, we are honored to extend our partnership with Drs. Michael and Paul Mann by providing the new Eye-Q system to their practices."

About Mann Eye Institute and Laser Center

For more than 20 years, Mann Eye Institute and Laser Center has been at the forefront of vision correction. Drs. Mike and Paul Mann are committed to personalized patient care, advanced surgical expertise and superior results. Their dedication has merited the practice a reputation for excellence in eye care. Thousands of patients from all over the world have trusted their vision to Mann Eye Institute and Laser Center's dedicated team of skilled professionals.

WaveLight AG (ISIN DE 000 512 5603)

WaveLight AG has been listed on Deutsch Borse AG's Prime Standard segment since January 2003: The company, which develops, manufactures and markets a full range of high-quality products for ophthalmology, specializes in vision optics. The market success of WaveLight is based on a dense sales network comprised of WaveLight's own sales channels as well as the sales channels of strategic partners.

Further information on WaveLight is available at: www.wavelight.com/eyes.

All information is given and all assessments are made on the basis of extremely conscientious research. However, no guarantee is given with regard to the information or assessments published. No liability whatsoever is accepted. The above statements do not represent an invitation to buy or sell securities. All rights reserved.

Disclaimer for Myopia:

        a. Approval of the premarket approval application is for the
           WaveLight ALLEGRETTO WAVE(R) Eye-Q Excimer Laser System to
           perform LASIK treatments in patients 18 years of age or
           older for the reduction or elimination of myopic refractive
           errors up to -12.0 diopters (D) of sphere with and without
           astigmatic refractive errors up to -6.0 D; and in patients
           with documented evidence of a stable manifest refraction
           defined as = 0.50 D of preoperative spherical equivalent
           shift over one year prior to surgery.
        b. LASIK is an elective procedure with the alternatives
           including but not limited to eyeglasses, contact lenses,
           photorefractive keratectomy (PRK), and other refractive
           surgeries.
        c. Approval of the application is based on clinical trials in
           the United States with 901 eyes treated, of which 813 of
           866 eligible eyes were followed for 12 months.
           Accountability at 3 months was 93.8%, at 6 months was
           91.9%, and at 12 months was 93.9%.
        d. The studies found that of the 844 eyes eligible for the
           uncorrected visual acuity (UCVA) analysis of effectiveness
           at the 3-month stability time point, 98.0% were corrected
           to 20/40 or better, and 84.4 % were corrected to 20/20 or
           better without spectacles or contact lenses.
        e. The clinical trials showed that the following subjective
           patient adverse events were reported as "moderate to
           severe" at a level at least 1% higher than baseline of the
           subjects at 3 months post-treatment: visual fluctuations
           (12.8% at baseline versus 28.6% at 3 months).
        f. Long term risks of LASIK for myopia with and without
           astigmatism beyond 12 months have not been studied.
        g. Note that the complete name for this ophthalmic laser is
           "WaveLight ALLEGRETTO WAVE(R) Eye-Q Excimer Laser System
           for laser assisted in situ keratomileusis (LASIK)
           treatments of myopic refractive errors up to -12.0
           diopters (D) of sphere with and without astigmatic
           refractive errors up to -6.0 D at the spectacle plane".

Disclaimer for Hyperopia:

        a. Approval of the premarket approval application is for the
           WaveLight ALLEGRETTO WAVE(R) Eye-Q Excimer Laser System to
           perform LASIK treatments in patients 18 years of age or
           older for the reduction or elimination of hyperopic
           refractive errors up to +6.0 diopters (D) of sphere with
           and without astigmatic refractive errors up to 5.0 D at the
           spectacle plane, with a maximum manifest refraction
           spherical equivalent (MRSE) of +6.0 D; and in patients with
           documented evidence of a stable manifest refraction defined
           as = 0.50 D of preoperative spherical equivalent shift
           over one year prior to surgery, exclusive of changes due to
           unmasking latent hyperopia.
        b. LASIK is an elective procedure with the alternatives
           including but not limited to eyeglasses, contact lenses,
           photorefractive keratectomy (PRK), and other refractive
           surgeries.
        c. Approval of the application is based on clinical trials in
           the United States with 290 eyes treated, of which 100 of
           290 eligible eyes were followed for 12 months.
           Accountability at 3 months was 95.2%, at 6 months was
           93.9%, and at 12 months was 69.9%.
        d. The studies found that of the 212 eyes eligible for the
           uncorrected visual acuity (UCVA) analysis of effectiveness
           at the 6-month stability time point, 95.3% were corrected
           to 20/40 or better, and 67.5 % were corrected to 20/20 or
           better without spectacles or contact lenses.
        e. The study showed that the following subjective patient
           adverse events were reported as "much worse" by at least
           1% of the subjects (in order of increasing frequency) at
           6 months post final treatment: glare from bright lights
           (3%); night driving glare (4.2%); light sensitivity (4.9%);
           visual fluctuations (6.1%); and halos (6.4%).
        f. Long term risks of LASIK for hyperopia with and without
           astigmatism beyond 12 months have not been studied.
        g. Note that the complete name for this ophthalmic laser is
           "WaveLight ALLEGRETTO WAVE(R) Eye-Q Excimer Laser System
           for laser assisted in situ keratomileusis (LASIK)
           treatments of hyperopic refractive errors up to +6.0
           diopters (D) of with and without astigmatic refractive
           errors up to 5.0 D with a maximum manifest refraction
           spherical equivalent (MRSE) of +6.0 D".